OKYO Pharma (NASDAQ: $OKYO), a clinical stage biopharmaceutical company, announced a major stability milestone for its drug candidate urcosimod on Monday, March 31, 2025. Details […]
Tag: NASDAQ
Alvotech (NASDAQ: ALVO) Releases Q4 Fiscal 2024 Results: Is This Biotech A Buy in 2025?
Alvotech (NASDAQ: $ALVO), a leading global biopharmaceutical manufacturer of biosimilars, released its Q4 fiscal 2024 results on Wednesday, March 26, 2024, after markets closed. Here […]
Intuitive Machines (NASDAQ: LUNR) Releases Q4 Fiscal 2024 Results: Is LUNR Still A Good Stock To Buy After Recent Failed Moon Mission?
Intuitive Machines (NASDAQ: $LUNR) is a leading space tech, infrastructure, and services company. It released its fourth-quarter fiscal 2024 results on Monday, 24 March 2025 […]
Five Below (NASDAQ: FIVE) Releases Q4 Fiscal 2024 Results: Is FIVE Still A Buy After The Latest Results?
Five Below (NASDAQ: $FIVE), a retailer that sells products priced at $5 or less released its Q4 fiscal on March 19, after markets closed. The […]
Science Applications International Corporation (NASDAQ: SAIC) Releases Q4 Fiscal 2025 Results: Is This The Perfect Buy Opportunity?
Science Applications International Corporation (NASDAQ: $SAIC), a tech company that provides government services, and IT support released its Q4 fiscal 2025 results on Monday, March […]
Hoth Therapeutics (NASDAQ: HOTH) Unveils Plan To Submit HT-001 Expanded Access Application Amid Double Digit Growth in The Past Week: What To Know About Hoth
Hoth Therapeutics (NASDAQ: $HOTH), a clinical-stage biopharmaceutical working to develop innovative therapies, announced on Monday, March 10, 2025, that it planned to submit an Expanded […]